Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-generation antipsychotics and their utilization decreased as use of oral second-generation antipsychotics (SGA) increased. Although registry-based naturalistic studies show LAIs reduce rehospitalization more than oral medications in clinical practice, this is not seen in recent randomized clinical trials. PROACTIVE (Preventing Relapse Oral Antipsychotics Compared to Injectables Evaluating Efficacy) relapse prevention study incorporated efficacy and effectiveness features. At 8 US academic centers, 305 patients with schizophrenia or schizoaffective disorder were randomly assigned to LAI risperidone (LAI-R) or physician's choice oral SGAs. Patients were evaluated during the 30-month study by masked, centralized assessors using 2-way video, and monitored biweekly by on-site clinicians and assessors who knew treatment assignment. Relapse was evaluated by a masked Relapse Monitoring Board. Differences between LAI-R and oral SGA treatment in time to first relapse and hospitalization were not significant. Psychotic symptoms and Brief Psychiatric Rating Scale total score improved more in the LAI-R group. In contrast, the LAI group had higher Scale for Assessment of Negative Symptoms Alogia scale scores. There were no other between-group differences in symptoms or functional improvement. Despite the advantage for psychotic symptoms, LAI-R did not confer an advantage over oral SGAs for relapse or rehospitalization. Biweekly monitoring, not focusing specifically on patients with demonstrated nonadherence to treatment and greater flexibility in changing medication in the oral treatment arm, may contribute to the inability to detect differences between LAI and oral SGA treatment in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552 · cited 1×
“Although age at first episode (23) and number of psychiatric hospitalizations (11) were comparable, LAI-R subjects had been hospitalized more recently (mean 22.”
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
A pragmatic–explanatory continuum indicator summary (PRECIS): a tool to help trial designers
Thorpe, K. E., Zwarenstein, M., Oxman, A. D., Treweek, S., Furberg, C. D., Altman, D. G., Tunis, S., Bergel, E., Harvey, I., Magid, D. J., et al. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.12.011 · Cited by 1,389
Tiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Csernansky, J. G., Mahmoud, R., & Brenner, R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa002028 · Cited by 605
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520
Self-citationMcGorry, P. D., Purcell, R., Goldstone, S., & Amminger, G. P. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283477a09 · Cited by 490
Kishimoto, T., Nitta, M., Borenstein, M., Kane, J. M., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08440 · Cited by 427
Self-citation
Cited by
Kishimoto, T., Hagi, K., Kurokawa, S., Kane, J. M., & Correll, C. U. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00039-0 · Cited by 369
Self-citationGuidelines for the Pharmacotherapy of Schizophrenia in Adults
Remington, G., Addington, D., Honer, W., Ismail, Z., Raedler, T., & Teehan, M. (2017) · The Canadian Journal of Psychiatry · doi:10.1177/0706743717720448 · Cited by 332
Marcus, S. C., Zummo, J., Pettit, A. R., Stoddard, J., & Doshi, J. A. (2015) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2015.21.9.754 · Cited by 248
“Since these effects of trial participation on adherence would introduce bias favoring the oral medication group, RCTs may systematically underestimate advantages of LAIs that might be seen with actual use in clinical practice.(22,23) Furthermore, most clinical trials, including the recent pragmatic randomized trial PR…”
BackgroundKishimoto, T., Hagi, K., Nitta, M., Leucht, S., Olfson, M., Kane, J. M., & Correll, C. U. (2018) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx090 · Cited by 186
“Subgroup analyses were based on (1) country, (2) region (North-America, Western Europe, Asia or others), (3) publication year (published before 2000, from 2000 to 2009, 2010 or later), (4) pharmaceutical sponsorship, (5) data source (single institution, multiple institutions, large database studies, including nationwi…”
BackgroundSelf-citationPaliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia.
Schreiner, A., Aadamsoo, K., Altamura, A. C., Franco, M., Gorwood, P., Neznanov, N. G., Schronen, J., Ucok, A., Zink, M., Janik, A., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.08.015 · Cited by 145
Metadata
- Authors
- Buckley, P. F., Schooler, N. R., Goff, D. C., Hsiao, J., Kopelowicz, A., Lauriello, J., Manschreck, T., Mendelowitz, A. J., Miller, D. D., Severe, J. B., Wilson, D. R., Ames, D., Bustillo, J., Mintz, J., Kane, J. M., & Study, T. P.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-05-27
- Volume
- 41
- Issue
- 2
- Pages
- 449-459
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2105929907
- Cited by
- 72
- References
- 8
- FWCI
- 7.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. https://app.cochat.ai/papers/10.1093/schbul/sbu067
- The paper
- Buckley, P. F., Schooler, N. R., Goff, D. C., Hsiao, J., Kopelowicz, A., Lauriello, J., Manschreck, T., Mendelowitz, A. J., Miller, D. D., Severe, J. B., Wilson, D. R., Ames, D., Bustillo, J., Mintz, J., Kane, J. M., & Study, T. P. (2015). Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbu067
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.